Fig. 1: Medium-sized animal RM/CS-AKI model rabbits were rescued with anti-Mb RabMAb.
From: Rescue RM/CS-AKI by blocking strategy with one-dose anti-myoglobin RabMAb
a Experimental design diagram of anti-Mb RabMAb treatment for RM/CS-AKI model rabbits. b, c Urine was collected after 24 h of RM/CS-AKI model rabbits injected with anti-Mb RabMAb. d, e WB detection of Mb abundance in the kidneys of RM/CS-AKI model rabbits after anti-Mb RabMAb treatment. GAPDH was used as the loading control. n = 3 biological replicates for each group (f, g) Immunohistochemistry staining was used to detect the Mb casts distribution in the kidney tissue, and HE staining was used to analyze the kidney injury of RM/CS-AKI model rabbits treated with anti-Mb RabMAb. h–o BUN, Cr, CK, and Mb concentration in rabbit serum and urine (p-values for pairs all indicated from left to right: p < 0.0001). p Representative images of transcutaneous disappearance curves of FITC-sinistrin excretion. The x-axis represents time, and the y-axis represents the relative transcutaneous fluorescence. q Terminal half-life (T1/2) of FITC-sinistrin excretion (p-values for pairs all indicated from left to right: p < 0.0001). r GFR values of each group of rabbits were calculated from the T1/2 of FITC-sinistrin (p-values for pairs all indicated from left to right: p < 0.0001). Graph bars represent mean ± SD, and dots indicate individual data points for n = 3 biological replicates with 2 technical replicates per group in (h–o, q, r). Two-way ANOVA for (h–o) and one-way ANOVA for (q, r) followed by Tukey’s multiple comparisons test were used to identify the differences. * p < 0.05, ** p < 0.01, *** p < 0.001. Source data are provided as a Source Data file.
